Therapy Detail

Therapy Name ABC294640
Therapy Description

Yeliva (ABC294640) is a selective inhibitor of sphingokinase 2 (SK2), which results in decreased SK2 activity, leading to reduced cell signaling and tumor cell growth (PMID: 26271487).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ABC294640 Yeliva Yeliva (ABC294640) is a selective inhibitor of sphingokinase 2 (SK2), which results in decreased SK2 activity, leading to reduced cell signaling and tumor cell growth (PMID: 26271487).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable ABC294640 Phase I Actionable In a Phase I trial, treatment with ABC294640 in patients with advanced solid tumors resulted in antitumor efficacy, including stable disease in six patients and a partial response in a patient with cholangiosarcoma (PMID: 28420720). 28420720
Clinical Trial Phase Therapies Title Recruitment Status
NCT02939807 Phase II ABC294640 A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma Recruiting
NCT02229981 Phase Ib/II ABC294640 An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma Withdrawn
NCT02757326 Phase Ib/II ABC294640 ABC294640 in Refractory / Relapsed Multiple Myeloma Recruiting
NCT03377179 Phase II ABC294640 A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma Recruiting